for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Incyte Corporation

INCY.O

Latest Trade

80.62USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

72.00

 - 

96.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Incyte Reports 2019 Third-Quarter Financial Results

Oct 29 (Reuters) - Incyte Corp <INCY.O>::INCYTE REPORTS 2019 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES UPDATES ON KEY CLINICAL PROGRAMS.Q3 NON-GAAP EARNINGS PER SHARE $0.82.Q3 EARNINGS PER SHARE ESTIMATE $0.65 -- REFINITIV IBES DATA.QTRLY TOTAL PRODUCT AND ROYALTY REVENUES OF $534 MILLION, UP 24%.RAISING FULL YEAR 2019 JAKAFI REVENUE GUIDANCE TO A NEW RANGE OF $1.65-1.68 BILLION.QTRLY TOTAL GAAP REVENUES $551.6 MILLION VERSUS $449.7 MILLION.Q3 REVENUE VIEW $536.5 MILLION -- REFINITIV IBES DATA.

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream In Patients With Vitiligo

Sept 25 (Reuters) - Incyte Corp <INCY.O>::INCYTE ANNOUNCES FIRST PATIENT TREATED IN PHASE 3 CLINICAL TRIAL PROGRAM EVALUATING RUXOLITINIB CREAM IN PATIENTS WITH VITILIGO.INCYTE - TRUE-V CLINICAL TRIAL PROGRAM INCLUDES 2 PHASE 3 STUDIES, TRUE-V1 AND TRUE-V2, EVALUATING SAFETY AND EFFICACY OF RUXOLITINIB CREAM IN PATIENTS WITH VITILIGO.INCYTE CORP - RUXOLITINIB CREAM IS CURRENTLY IN PHASE 3 DEVELOPMENT WITH INITIAL RESULTS EXPECTED IN FIRST HALF OF 2020.

Lilly Announces Top-Line Phase 3 Results For Oral JAK Inhibitor Baricitinib, In Combination With Topical Corticosteroids In Adult Patients With Moderate To Severe Atopic Dermatitis

Aug 23 (Reuters) - Eli Lilly And Co::LILLY ANNOUNCES TOP-LINE PHASE 3 RESULTS FOR ORAL JAK INHIBITOR BARICITINIB, IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.ELI LILLY AND CO - BARICITINIB MET PRIMARY ENDPOINT IN BREEZE-AD7, THIRD PIVOTAL PHASE 3 TRIAL IN BREEZE-AD PROGRAM TO BE COMPLETED IN 2019.ELI LILLY AND CO - MOST COMMON TREATMENT-EMERGENT ADVERSE EVENTS OBSERVED WERE NASOPHARYNGITIS, UPPER RESPIRATORY TRACT INFECTION AND FOLLICULITIS.ELI LILLY AND CO - SAFETY DATA WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF BARICITINIB.ELI LILLY AND CO - NO MALIGNANCIES, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), OR DEATHS WERE REPORTED IN STUDY.

Incyte Qtrly Earnings Per Share $0.48

July 30 (Reuters) - Incyte Corp <INCY.O>::INCYTE REPORTS 2019 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES UPDATES ON KEY CLINICAL PROGRAMS.QTRLY TOTAL PRODUCT AND ROYALTY REVENUES OF $510 MILLION (+21% VERSUS. Q2 2018).RAISING BOTTOM END OF FULL YEAR 2019 JAKAFI REVENUE GUIDANCE TO A NEW RANGE OF $1.61-1.65 BILLION.QTRLY EARNINGS PER SHARE $0.48.Q2 EARNINGS PER SHARE VIEW $0.48, REVENUE VIEW $497.8 MILLION -- REFINITIV IBES DATA.

Incyte And Zai Lab Announce Collaboration And License Agreement For Incmga0012 In Greater China

July 2 (Reuters) - Incyte Corp <INCY.O>::INCYTE AND ZAI LAB ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR INCMGA0012 IN GREATER CHINA.ZAI LAB LTD - COLLABORATION AND LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF INCMGA0012 IN GREATER CHINA.ZAI LAB LTD - ZAI LAB WILL PAY INCYTE US$17.5 MILLION UP FRONT.ZAI LAB LTD - INCYTE IS ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL US$60 MILLION IN POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES.ZAI LAB LTD - TO GET RIGHTS TO DEVELOP, COMMERCIALIZE INCMGA0012 IN HEMATOLOGY AND ONCOLOGY IN MAINLAND CHINA, HONG KONG, MACAU AND TAIWAN.ZAI LAB LTD - INCYTE WILL RETAIN OPTION TO ASSIST IN PROMOTION OF INCMGA0012 IN ZAI LAB'S LICENSED TERRITORIES.

FDA Approves Jakafi For The Treatment Of Patients With Acute Graft-Versus-Host Disease

May 24 (Reuters) - Incyte Corp <INCY.O>::FDA APPROVES JAKAFI® (RUXOLITINIB) FOR THE TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE.INCYTE CORP - JAKAFI WILL BE MADE AVAILABLE TO APPROPRIATE PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD IMMEDIATELY..INCYTE CORP - FDA APPROVED JAKAFI (RUXOLITINIB) FOR TREATMENT OF STEROID-REFRACTORY ACUTE GVHD IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER.

Incyte Corp QTRLY Adjusted Diluted Earnings Per Share $0.62

Incyte Corp <INCY.O>::INCYTE REPORTS 2019 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES UPDATES ON KEY CLINICAL PROGRAMS.Q1 REVENUE $498 MILLION VERSUS REFINITIV IBES ESTIMATE OF $486.2 MILLION.QTRLY BASIC GAAP EARNINGS PER SHARE $0.48.QTRLY DILUTED GAAP EARNINGS PER SHARE $0.47.QTRLY ADJUSTED DILUTED EARNINGS PER SHARE $0.62.QTRLY ADJUSTED BASIC EARNINGS PER SHARE $0.63.PRIMARY ENDPOINT MET IN PHASE 2 TRIAL OF RUXOLITINIB CREAM FOR TREATMENT OF VITILIGO.DECISION TAKEN TO NO LONGER PARTICIPATE IN CO-FUNDING OF DEVELOPMENT OF BARICITINIB.SEES 2019 GAAP RESEARCH AND DEVELOPMENT EXPENSES OF $1,185 MILLION - $1,255 MILLION.Q1 EARNINGS PER SHARE VIEW $0.40, REVENUE VIEW $486.2 MILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.94, REVENUE VIEW $2.05 BILLION -- REFINITIV IBES DATA.

Briacell Announces Clinical Trial Collaboration Agreement With Incyte

April 2 (Reuters) - Briacell Therapeutics Corp <BCT.V>::BRIACELL ANNOUNCES CLINICAL TRIAL COLLABORATION AGREEMENT WITH INCYTE.BRIACELL THERAPEUTICS - CO, INCYTE FORMED NON-EXCLUSIVE CLINICAL TRIAL COLLABORATION TO EVALUATE EFFECTS OF COMBINATIONS OF NOVEL CLINICAL CANDIDATES.BRIACELL THERAPEUTICS CORP - UNDER AGREEMENT, INCYTE WILL PROVIDE COMPOUNDS FROM ITS DEVELOPMENT PORTFOLIO.

Incyte Announces U.S. FDA Has Extended The Review Period For Ruxolitinib (Jakafi) In Acute Graft-Versus-Host Disease

Feb 7 (Reuters) - Incyte Corp <INCY.O>::INCYTE ANNOUNCES U.S. FDA HAS EXTENDED THE REVIEW PERIOD FOR RUXOLITINIB (JAKAFI®) IN ACUTE GRAFT-VERSUS-HOST DISEASE.INCYTE CORP - FDA EXTENDED ACTION DATE TO ALLOW TIME TO REVIEW ADDITIONAL DATA SUBMITTED BY INCYTE IN RESPONSE TO FDA'S INFORMATION REQUESTS.INCYTE CORP - AN EXTENSION OF PDUFA GOAL DATE BY THREE MONTHS.INCYTE CORP - NEW PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE IS MAY 24, 2019.

Lilly Announces Top-Line Phase 3 Results For Baricitinib In Patients With Moderate To Severe Atopic Dermatitis

Feb 4 (Reuters) - Eli Lilly and Co <LLY.N> and Incyte Corp <INCY.O>::LILLY ANNOUNCES TOP-LINE PHASE 3 RESULTS FOR BARICITINIB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.INCYTE CORP - BARICITINIB MET PRIMARY ENDPOINT IN BREEZE-AD1 AND BREEZE-AD2.INCYTE - IN BOTH INVESTIGATIONAL TRIALS STATISTICALLY SIGNIFICANT PROPORTION OF PATIENTS TREATED WITH BARICITINIB ACHIEVED PRIMARY ENDPOINT AT WEEK 16.INCYTE - SERIOUS ADVERSE EVENTS WITH BARICITINIB TREATMENT WAS SIMILAR TO PLACEBO.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up